Ophthalmic Sustained Release Device Using Intraocular Gas
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein/peptide preparations, such as antibody drugs, have short duration of action requiring frequent administration and pose side effects due to high concentration, and conventional sustained release technologies face challenges with water solubility and high molecular weight, leading to deactivation during processing.
Innovation Solution
A device with a hollow container containing a drug enclosing part isolated by an intraocular retention gas enclosing part, where intraocular fluid dissolves the gas, allowing gradual drug release over time, maintaining efficacy with reduced frequency and side effects, and enabling storage stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sustained release technologies are used for protein/peptide preparations, then drug release control is achieved, but the drug deactivates during processing due to water solubility and high molecular weight
Solution Approach 1:
The invention changes the physical state of the protein/peptide drug from liquid to solid by freeze-drying, and changes the release mechanism from direct diffusion to gas-pressure-driven release. The drug is freeze-dried into a porous solid state that can be enclosed in a container, and release is achieved by gas pressure generated from intraocular retention gas, avoiding the need for liquid formulation processing that causes deactivation.
Solution Approach 2:
The invention introduces intraocular retention gas as an intermediary substance that serves dual purposes: it provides gas pressure to drive drug release and acts as a sealing agent. The gas pressure mechanism mediates the release process without requiring direct contact between the drug and processing fluids that would cause deactivation.
2Reliability
If high concentration antibody drugs are administered, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The invention implements periodic action by providing sustained release of the drug over an extended period (months to years) through gas pressure-driven release. This converts the need for frequent high-dose administrations into a single low-dose administration that releases gradually, maintaining therapeutic efficacy while reducing peak concentration-related side effects.
Solution Approach 2:
The invention applies preliminary action by pre-enclosing the drug in solid form within the container before implantation. The drug is prepared in advance in a stable solid state, and the release is controlled by the gradual dissolution of intraocular retention gas, allowing prolonged therapeutic effect at lower concentrations.
3Reliability
If frequent administration is performed to maintain efficacy, then therapeutic effect is maintained, but administration burden and side effects increase
Solution Approach 1:
The invention achieves continuity of useful action by providing sustained drug release over an extended period through the gradual dissolution of intraocular retention gas. The gas pressure continuously drives drug release from the container, maintaining therapeutic effect without requiring repeated administrations, thereby eliminating administration burden and associated side effects.
4Adaptability or versatility
If multiple container types are prepared for different drugs, then drug-specific optimization is achieved, but manufacturing complexity increases
Solution Approach 1:
The invention applies universality by designing a single standardized container type that can enclose different protein/peptide drugs. The container design with intraocular retention gas enclosing part and drug enclosing part is universal and can be used for various drugs by simply changing the drug formulation, eliminating the need for multiple specialized container types while maintaining drug-specific optimization capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device achieves sustained drug release over a long period, reducing administration frequency and side effects, while maintaining drug efficacy and storage stability, and allows for the use of a single container type for various drugs.
Implementation Method 1
The inflowing intraocular fluid dissolves the intraocular retention gas and the residual amount of the intraocular retention gas gradually decreases
Implementation Method 2
the drug enclosed in the drug enclosing part dissolves and diffuses to be released to the outside of the container
Data Source
AI summary
An object of the present invention is to provide a sustained drug release system useful for treating eye diseases. There is provided a device for sustained release of an ophthalmic drug, comprising a drug enclosing part and an intraocular retention gas enclosing part adjacent to the drug enclosing part, the enclosing parts being provided in a hollow container having at least one opening part, wherein the drug enclosing part is isolated from the opening part by the intervention of the intraocular retention gas enclosing part.